- Home
- CHX vs IONS Comparison
CHX vs IONS Comparison
Compare CHX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHX
- IONS
- Stock Information
- Founded
- CHX 1882
- IONS 1989
- Country
- CHX United States
- IONS United States
- Employees
- CHX N/A
- IONS N/A
- Industry
- CHX Industrial Machinery/Components
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CHX Industrials
- IONS Health Care
- Exchange
- CHX Nasdaq
- IONS Nasdaq
- Market Cap
- CHX 6.0B
- IONS 6.0B
- IPO Year
- CHX N/A
- IONS 1991
- Fundamental
- Price
- CHX $31.24
- IONS $34.01
- Analyst Decision
- CHX Buy
- IONS Buy
- Analyst Count
- CHX 4
- IONS 18
- Target Price
- CHX $39.00
- IONS $62.00
- AVG Volume (30 Days)
- CHX 1.7M
- IONS 1.4M
- Earning Date
- CHX 10-23-2024
- IONS 11-06-2024
- Dividend Yield
- CHX 1.22%
- IONS N/A
- EPS Growth
- CHX 7.15
- IONS N/A
- EPS
- CHX 1.62
- IONS N/A
- Revenue
- CHX $3,665,501,000.00
- IONS $803,067,000.00
- Revenue This Year
- CHX N/A
- IONS N/A
- Revenue Next Year
- CHX $3.90
- IONS $16.31
- P/E Ratio
- CHX $19.29
- IONS N/A
- Revenue Growth
- CHX N/A
- IONS 30.57
- 52 Week Low
- CHX $25.46
- IONS $33.33
- 52 Week High
- CHX $39.95
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- CHX 56.97
- IONS 32.90
- Support Level
- CHX $30.28
- IONS $33.33
- Resistance Level
- CHX $32.08
- IONS $35.65
- Average True Range (ATR)
- CHX 0.77
- IONS 1.55
- MACD
- CHX 0.12
- IONS -0.36
- Stochastic Oscillator
- CHX 77.30
- IONS 10.09
About CHX ChampionX Corporation
ChampionX provides chemical solutions and equipment for onshore and offshore oil and gas production. Its engineering expertise spans the well lifecycle, but the firm maintains a particular focus on the production phase. Key offerings include artificial lift services and drilling technologies, specializing in polycrystalline diamond cutter inserts. ChampionX was formed after Apergy acquired its chemical technologies business from Ecolab in 2020.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.